Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that wants to combine conventional medications with psychedelic research for people suffering from conditions like post-traumatic stress disorder (PTSD), Alzheimer’s disease, and other rare neurological diseases. Silo aims to discover assets that can be licensed and financed so that important research may be done, which the company believes will benefit patients and the healthcare sector. Silo Pharma The post Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment appeared first on Psychedelic Chronicle.